DK1316801T3 - Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer - Google Patents

Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer

Info

Publication number
DK1316801T3
DK1316801T3 DK02256808T DK02256808T DK1316801T3 DK 1316801 T3 DK1316801 T3 DK 1316801T3 DK 02256808 T DK02256808 T DK 02256808T DK 02256808 T DK02256808 T DK 02256808T DK 1316801 T3 DK1316801 T3 DK 1316801T3
Authority
DK
Denmark
Prior art keywords
detecting
topology
compositions
methods
treating diseases
Prior art date
Application number
DK02256808T
Other languages
Danish (da)
English (en)
Inventor
Jennifer M Burns
Zhenhua Miao
Zheng Wei
Maureen C Howard
Brett A Premack
Thomas J Schall
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Application granted granted Critical
Publication of DK1316801T3 publication Critical patent/DK1316801T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK02256808T 2001-11-30 2002-09-30 Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer DK1316801T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33810001P 2001-11-30 2001-11-30
US10/245,850 US7442512B2 (en) 2001-11-30 2002-09-16 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

Publications (1)

Publication Number Publication Date
DK1316801T3 true DK1316801T3 (da) 2006-03-06

Family

ID=26937511

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02256808T DK1316801T3 (da) 2001-11-30 2002-09-30 Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer

Country Status (10)

Country Link
US (1) US7442512B2 (de)
EP (2) EP1316801B1 (de)
JP (1) JP4485204B2 (de)
KR (1) KR100961237B1 (de)
AT (1) ATE310955T1 (de)
AU (1) AU2002351213B2 (de)
CA (1) CA2468407A1 (de)
DE (1) DE60207514T2 (de)
DK (1) DK1316801T3 (de)
WO (1) WO2003047420A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
EP1365245A1 (de) * 2002-05-23 2003-11-26 Bayer Aktiengesellschaft Diagnostika und Therapeutika von mit Chemokine Rezeptor 11 (CCR11) assoziierten Krankheiten
US7964194B2 (en) * 2002-11-15 2011-06-21 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
KR101374514B1 (ko) * 2003-12-10 2014-03-13 메다렉스, 인코포레이티드 Ｉｐ―１０ 항체 및 그의 용도
EP1723970A4 (de) * 2004-03-09 2009-08-12 Univ Kyoto Medizinische zusammensetzung mit cxcr3-hemmer
CN100357738C (zh) * 2004-03-26 2007-12-26 博奥生物有限公司 一种检测小分子化合物的方法
CA2501422C (en) * 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
US20100143899A1 (en) * 2005-05-17 2010-06-10 University Of Vermont And State Agricultural College Methods and products for diagnosing cancer
CN101243319B (zh) * 2005-06-22 2016-01-06 约翰·霍普金斯大学 卵巢癌的生物标记：ctap3-相关蛋白质
RU2449808C2 (ru) 2006-04-21 2012-05-10 Сентокор, Инк. Антагонисты cxcl13 и их применение для лечения воспалительных заболеваний
GB0614755D0 (en) * 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
ES2625798T3 (es) * 2006-10-02 2017-07-20 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US8445442B2 (en) * 2007-04-26 2013-05-21 University Of Vermont And State Agricultural College CCL18 and CCL3 methods and compositions for detecting and treating cancer
ES2477294T3 (es) * 2007-08-13 2014-07-16 Baxter International Inc Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson
CA2698115A1 (en) * 2007-08-31 2009-03-05 Massachusetts Institute Of Technology Treatment of autoimmune disease
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
EP2552962B1 (de) 2010-03-26 2016-03-23 Ablynx N.V. Einzelne, gegen cxcr7 gerichtete variable immunoglobulindomänen
EP2611832B1 (de) 2010-09-02 2017-11-29 Vaccinex, Inc. Anti-cxcl13-antikörper und verfahren zu ihrer verwendung
EA037063B1 (ru) * 2010-11-08 2021-02-01 Аблинкс Н.В. Cxcr2-связывающие полипептиды
AR084141A1 (es) 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20
EP2691418A1 (de) 2011-03-28 2014-02-05 Ablynx N.V. Bispezifische gegen cxcr4 gerichtete variable immglobulineinzeldomänen
KR101359317B1 (ko) * 2011-08-23 2014-02-10 건양대학교산학협력단 Ｄ6 디코이 수용체의 세포 외 도메인 1을 포함하는 항암용 약학 조성물
CN104520323B (zh) 2012-03-02 2018-05-04 瓦西尼斯公司 用于治疗b细胞介导的炎性疾病的方法
EP2682187B1 (de) * 2012-07-02 2017-09-13 Molecular Devices, LLC Auswahlverfahren und -vorrichtung
US9718887B2 (en) 2012-09-06 2017-08-01 Adelaide Research & Innovation Pty Ltd Methods and products for preventing and/or treating metastatic cancer
JP6363623B2 (ja) 2013-01-31 2018-07-25 ヴァクシネックス， インコーポレイテッド 免疫グロブリンａのレベルを増大するための方法
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
EP3666282A1 (de) 2015-06-03 2020-06-17 The Medical College of Wisconsin, Inc. Manipuliertes ccl20-locked-dimer-polypeptid
WO2016207124A1 (en) * 2015-06-25 2016-12-29 F. Hoffmann-La Roche Ag Cell based assay for determining antibody or ligand binding and function
EP3533465A4 (de) 2016-09-26 2020-07-01 MPO, Inc. Ei, befruchtete eizelle oder mittel zur verbesserung der embryoqualität
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
CN107312092B (zh) * 2017-05-04 2020-12-11 华南农业大学 一种斜带石斑鱼ccr12的多克隆抗体制备方法及其应用
CN113684238A (zh) * 2021-08-09 2021-11-23 广州医科大学附属第一医院（广州呼吸中心） Cxc趋化因子受体3作为咳嗽药物靶点的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4927838A (en) * 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
US6537764B1 (en) 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
SE9600820D0 (sv) * 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
ATE360689T1 (de) 1996-09-10 2007-05-15 Kocher Theodor Inst Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
US5876946A (en) * 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
EP0897980A3 (de) 1997-08-20 2002-04-17 Smithkline Beecham Corporation CXCR4B: Eine menschliche Spleissvariante des CXCR4 Chemokinrezeptors
US6306653B1 (en) * 1998-01-20 2001-10-23 Codon Diagnostics, Llc Detection and treatment of breast disease
EP2308996A1 (de) 1998-03-30 2011-04-13 NorthWest Biotherapeutics, Inc. Therapeutische und diagnostische Anwendungen auf Grundlage der Wirkung der CXCR-4 und SDF-1 Gene in der Tumorigenese
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6449054B1 (en) * 1998-08-01 2002-09-10 Canon Kabushiki Kaisha Dynamic assignment of group addresses for controlling parallel peripheral devices
US6329510B1 (en) * 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US6365356B1 (en) * 1999-03-17 2002-04-02 Cornell Research Foundation, Inc. Receptors that regulate cell signaling relating to chemokines
AU4230900A (en) * 1999-04-08 2000-10-23 General Hospital Corporation, The Purposeful movement of human migratory cells away from an agent source
US20020061599A1 (en) * 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
AU2001243145A1 (en) * 2000-02-09 2001-08-20 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
US20020064770A1 (en) * 2000-03-21 2002-05-30 Nestor John J. Binding compounds and methods for identifying binding compounds
US20020025536A1 (en) * 2000-06-26 2002-02-28 Jeno Gyuris Methods and reagents for isolating biologically active antibodies

Also Published As

Publication number Publication date
CA2468407A1 (en) 2003-06-12
JP4485204B2 (ja) 2010-06-16
AU2002351213A1 (en) 2003-06-17
AU2002351213B2 (en) 2008-01-03
EP1316801A1 (de) 2003-06-04
US20030124628A1 (en) 2003-07-03
JP2005527189A (ja) 2005-09-15
EP1461061A2 (de) 2004-09-29
US7442512B2 (en) 2008-10-28
WO2003047420A3 (en) 2004-02-26
EP1316801B1 (de) 2005-11-23
EP1461061A4 (de) 2005-08-31
DE60207514D1 (de) 2005-12-29
AU2002351213B8 (en) 2003-06-17
KR100961237B1 (ko) 2010-06-03
WO2003047420A2 (en) 2003-06-12
DE60207514T2 (de) 2006-08-10
KR20040099258A (ko) 2004-11-26
ATE310955T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2003047420A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
ATE544870T1 (de) Profilierung einer rezeptorfamilie
EP2101772A4 (de) Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon
EA200702617A1 (ru) Антагонисты мускариновых ацетилхолиновых рецепторов
MA29528B1 (fr) Agents de fixation
TR200300322T2 (tr) Kemokin alıcısını bağlayan heterosiklik bileşikler
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
ATE424560T1 (de) Marker für neuromyelitis optica
NO20065417L (no) Muskarine acetylkolinreceptorantagonister
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
DE602005022319D1 (de) Modifizierte pyrimidin-glucocorticoid-rezeptor-modulatoren
MA30922B1 (fr) Anticorps d'agonistes de trkb et leurs utilisations
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
WO2007111938A3 (en) Inflammation-inhibitory serum factors and uses thereof
DE60328069D1 (de) Test-Photomaske, Streulichtbewertungsverfahren, und Streulichtkompensierungsverfahren
WO2004108887A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
NO20060775L (no) Muskarine acetylkolinreseptorantagonister
HRP20041224A2 (en) Cck-1 receptor modulators
BR0015872A (pt) Agentes antitrombóticos
NO20002408L (no) 5-HT1F antagonister
DE60321497D1 (de) Zusammensetzung für Flüssigtoner
NO20064715L (no) Deteksjon, isolering og anvendelse av renalase (monoamin aksidase C)
FI20031191A7 (fi) Monoamiinin takaisinoton estäjä
DK1613772T3 (da) Fremgangsmåde til bestemmelse af tilstanden af jord